OBI Pharma, Inc. (4174.TWO)
TWD 55.8
(-10.0%)
TWD 55.8
(-10.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -398.22 Million TWD | 91.14% |
| 2022 | -4.49 Billion TWD | -102.51% |
| 2021 | -2.21 Billion TWD | 28.45% |
| 2020 | -3.1 Billion TWD | 29.08% |
| 2019 | -4.37 Billion TWD | -21.38% |
| 2018 | -3.6 Billion TWD | -45.02% |
| 2017 | -2.48 Billion TWD | -86.22% |
| 2016 | -1.33 Billion TWD | 42.01% |
| 2015 | -2.3 Billion TWD | -156.48% |
| 2014 | -896.95 Million TWD | 29.47% |
| 2013 | -1.27 Billion TWD | -183.39% |
| 2012 | -448.76 Million TWD | -699.24% |
| 2011 | -56.14 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -777 Million TWD | -95.12% |
| 2024 Q2 | -616.47 Million TWD | 20.66% |
| 2023 Q1 | -4.43 Billion TWD | 1.42% |
| 2023 FY | -398.22 Million TWD | 91.14% |
| 2023 Q2 | -2.5 Billion TWD | 43.42% |
| 2023 Q3 | -1.55 Billion TWD | 38.11% |
| 2023 Q4 | -398.22 Million TWD | 74.33% |
| 2022 FY | -4.49 Billion TWD | -102.51% |
| 2022 Q4 | -4.49 Billion TWD | 6.83% |
| 2022 Q3 | -4.82 Billion TWD | -5.5% |
| 2022 Q2 | -4.57 Billion TWD | 7.27% |
| 2022 Q1 | -4.93 Billion TWD | -122.19% |
| 2021 Q2 | -3.29 Billion TWD | 6.16% |
| 2021 Q1 | -3.5 Billion TWD | -13.05% |
| 2021 Q4 | -2.21 Billion TWD | 22.17% |
| 2021 Q3 | -2.85 Billion TWD | 13.34% |
| 2021 FY | -2.21 Billion TWD | 28.45% |
| 2020 Q1 | -3.98 Billion TWD | 8.76% |
| 2020 Q2 | -3.54 Billion TWD | 11.23% |
| 2020 Q3 | -3.33 Billion TWD | 5.79% |
| 2020 Q4 | -3.1 Billion TWD | 7.05% |
| 2020 FY | -3.1 Billion TWD | 29.08% |
| 2019 Q2 | -5.01 Billion TWD | -54.16% |
| 2019 FY | -4.37 Billion TWD | -21.38% |
| 2019 Q4 | -4.37 Billion TWD | 6.99% |
| 2019 Q3 | -4.7 Billion TWD | 6.31% |
| 2019 Q1 | -3.25 Billion TWD | 9.65% |
| 2018 FY | -3.6 Billion TWD | -45.02% |
| 2018 Q1 | -3.87 Billion TWD | -55.9% |
| 2018 Q4 | -3.6 Billion TWD | 7.17% |
| 2018 Q3 | -3.88 Billion TWD | 8.93% |
| 2018 Q2 | -4.26 Billion TWD | -10.03% |
| 2017 FY | -2.48 Billion TWD | -86.22% |
| 2017 Q4 | -2.48 Billion TWD | 9.94% |
| 2017 Q3 | -2.75 Billion TWD | 8.91% |
| 2017 Q2 | -3.02 Billion TWD | -2.53% |
| 2017 Q1 | -2.95 Billion TWD | -121.39% |
| 2016 Q2 | -1.25 Billion TWD | -8.92% |
| 2016 Q4 | -1.33 Billion TWD | -25.8% |
| 2016 Q3 | -1.06 Billion TWD | 15.42% |
| 2016 FY | -1.33 Billion TWD | 42.01% |
| 2016 Q1 | -1.15 Billion TWD | 49.96% |
| 2015 Q3 | -3.18 Billion TWD | -17.68% |
| 2015 Q4 | -2.3 Billion TWD | 27.71% |
| 2015 Q2 | -2.7 Billion TWD | 61.23% |
| 2015 Q1 | -6.97 Billion TWD | -677.62% |
| 2015 FY | -2.3 Billion TWD | -156.48% |
| 2014 Q1 | 1.27 Billion TWD | 200.1% |
| 2014 FY | -896.95 Million TWD | 29.47% |
| 2014 Q4 | -896.95 Million TWD | 2.62% |
| 2014 Q3 | -921.09 Million TWD | 11.84% |
| 2014 Q2 | -1.04 Billion TWD | -182.07% |
| 2013 Q2 | -520.9 Million TWD | -172.32% |
| 2013 FY | -1.27 Billion TWD | -183.39% |
| 2013 Q1 | 720.3 Million TWD | 260.51% |
| 2013 Q4 | -1.27 Billion TWD | 0.0% |
| 2012 Q3 | -450.33 Million TWD | 0.0% |
| 2012 Q4 | -448.76 Million TWD | 0.35% |
| 2012 FY | -448.76 Million TWD | -699.24% |
| 2011 FY | -56.14 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -77.04 Million TWD | -416.879% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | -264.16 Million TWD | -50.746% |
| Level Biotechnology Inc. | -453.9 Million TWD | 12.267% |
| Sagittarius Life Science Corp | -120.57 Million TWD | -230.284% |
| NeoCore Technology Co., Ltd. | -196.39 Million TWD | -102.765% |
| TaiMed Biologics Inc. | 499.84 Million TWD | 179.669% |
| GlycoNex Incorporation | -148.56 Million TWD | -168.043% |
| VBI | -25.31 Million TWD | -1473.013% |
| GeneReach Biotechnology Corp. | 40.26 Million TWD | 1088.983% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 137.99 Million TWD | 388.579% |
| SynCore Biotechnology Co.,Ltd | -262.58 Million TWD | -51.657% |
| Genomics BioSci & Tech. Co.,Ltd. | 30.57 Million TWD | 1402.322% |
| Visgeneer Inc. | 31.28 Million TWD | 1372.932% |
| Mycenax Biotech Inc. | 207 Million TWD | 292.37% |
| Sunmax Biotechnology Co., Ltd. | -680.6 Million TWD | 41.49% |
| G&E Herbal Biotechnology Co., Ltd. | -134.25 Million TWD | -196.624% |
| Neith Corporation | -150.31 Million TWD | -164.933% |
| Medigen Vaccine Biologics Corporation | 621.53 Million TWD | 164.071% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -57.65 Million TWD | -590.666% |
| Enimmune corporation | -314.15 Million TWD | -26.759% |
| TaiRx, Inc. | -147.86 Million TWD | -169.309% |
| CHO Pharma, Inc. | -203.79 Million TWD | -95.407% |
| EirGenix Inc. | -4.58 Billion TWD | 91.32% |
| BioLASCO Taiwan Co., Ltd. | -84.76 Million TWD | -369.809% |
| Sunny Pharmtech Inc. | 120.87 Million TWD | 429.462% |
| Lin BioScience, Inc. | -3.21 Billion TWD | 87.626% |
| BioGend Therapeutics Co., Ltd. | -317.41 Million TWD | -25.457% |
| Feng Chi Biotech Corp. | -19.81 Million TWD | -1909.913% |
| Bio Preventive Medicine Corp. | 31.8 Million TWD | 1351.922% |
| Lukas Biomedical Inc. | 50.75 Million TWD | 884.601% |
| RBC Bioscience Corporation | 422.18 Million TWD | 194.325% |
| BiOptic Inc. | 12.59 Million TWD | 3262.516% |
| BRIM Biotechnology, Inc. | -944.4 Million TWD | 57.833% |
| Shine-On BioMedical Co.,Ltd. | -101.48 Million TWD | -292.393% |
| Great Novel Therapeutics Biotech & Medicals | -165.17 Million TWD | -141.091% |
| Syngen Biotech Co.,Ltd. | 314.87 Million TWD | 226.471% |
| Advagene Biopharma Co., Ltd. | -64.32 Million TWD | -519.12% |
| NaviFUS Corp. | -123.12 Million TWD | -223.42% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 74.05 Million TWD | 637.77% |
| Sinew Pharma Inc. | -160.34 Million TWD | -148.354% |
| Andros Pharmaceuticals Co.,Ltd | -241.89 Million TWD | -64.628% |
| Greenyn Biotechnology Co., Ltd | -337.37 Million TWD | -18.036% |
| Lumosa Therapeutics Co., Ltd. | -412.63 Million TWD | 3.493% |
| AP Biosciences Inc | -196.52 Million TWD | -102.63% |
| Medigen Biotechnology Corp. | 688.73 Million TWD | 157.82% |
| 3D Global Biotech Inc. | -11.43 Million TWD | -3381.892% |
| Pharmosa Biopharm Inc. | -829.69 Million TWD | 52.003% |
| Intech Biopharm Corporation | 1.35 Billion TWD | 129.339% |
| Oneness Biotech Co., Ltd. | -414.87 Million TWD | 4.014% |
| Eusol Biotech Co.,Ltd. | -209.33 Million TWD | -90.23% |
| TWi Biotechnology, Inc. | -143.86 Million TWD | -176.808% |
| Ever Supreme Bio Technology Co., Ltd | -330.54 Million TWD | -20.476% |
| TCI GENE Inc. | -689.25 Million TWD | 42.224% |
| MegaPro Biomedical Co., Ltd | -118.93 Million TWD | -234.816% |
| Senhwa Biosciences, Inc. | -1.3 Billion TWD | 69.583% |
| Taiwan Bio Therapeutics Co., Ltd | 20.48 Million TWD | 2044.168% |
| NatureWise Biotech & Medicals Corporation | -101.87 Million TWD | -290.914% |
| PharmaEngine, Inc. | -860.8 Million TWD | 53.738% |
| Savior Lifetec Corporation | -812.54 Million TWD | 50.99% |
| TaiGen Biopharmaceuticals Holdings Limited | -299.96 Million TWD | -32.755% |
| Meribank Biotech Co., Ltd | -365.41 Million TWD | -8.977% |
| Acepodia, Inc. | -6.02 Billion TWD | 93.385% |
| Caliway Biopharmaceuticals Co., Ltd. | -3.4 Billion TWD | 88.293% |